Results 201 to 210 of about 176,773 (340)

Discriminative Information in the Diagnosis of Dysphagia

, 1975
David A. Edwards
openalex   +1 more source

Treatment of Cervical Spondylosis With Dysphagia Caused by Anterior Osteophytes: A Retrospective Case Series Study. [PDF]

Global Spine J
Chen R, Wang B, Zhao Y, Diao Y, Chen X, Pan S, Zhang F, Sun Y, Zhou F, Liu Z.   +9 more
europepmc   +1 more source

Correlations between Dysphagia Severity Scale Scores and Clinical Indices in Individuals with Multiple System Atrophy

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Dysphagia significantly impacts prognosis in individuals with multiple system atrophy (MSA). While video‐based assessments are practical, their limited availability highlights the need for a simple tool such as the Dysphagia Severity Scale (DSS) in clinical practice.
Ryunosuke Nagao, Yasuaki Mizutani, Kazuya Kawabata, Junichiro Yoshimoto, Yoko Inamoto, Seiko Shibata, Mizuki Ito, Yohei Otaka, Hirohisa Watanabe   +8 more
wiley   +1 more source

Dysphagia education in Addis Ababa, Ethiopia: student self-competency ratings during their dysphagia course. [PDF]

BMC Med Educ
Smaoui S, Ganesan S, Williams T.
europepmc   +1 more source

Dysphagia caused by a large pulmonary bulla [PDF]

, 1994
Hitoshi Ueda, Takuo Kusano, Akinori Iwasaki   +2 more
openalex   +1 more source

Dysphagia

International Journal of Clinical Practice, 1965
openaire   +2 more sources

Cervical proprioception and dysphagia severity in multiple sclerosis: A cross-sectional clinical analysis. [PDF]

Eur J Oral Sci
Abakay H, Yetkin MF, Güç A, Şekercan G.   +3 more
europepmc   +1 more source

Long‐Term Safety and Efficacy of Repeat Treatments with DaxibotulinumtoxinA in Cervical Dystonia: Results from the ASPEN‐Open‐Label Study

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background DaxibotulinumtoxinA (DAXI), a novel botulinum neurotoxin (BoNT) formulation, was shown to be safe, effective, and long‐lasting in the treatment of cervical dystonia (CD) over one treatment cycle in the phase 3, randomized, placebo‐controlled ASPEN‐1 trial.
Peter McAllister, Atul T. Patel, Marta Banach, Aaron Ellenbogen, Jaroslaw Slawek, Sebastian Paus, Hyder A. Jinnah, Virgilio Evidente, Todd M. Gross, Rashid Kazerooni, Conor J. Gallagher, David A. Hollander   +11 more
wiley   +1 more source

Dysphagia in Frail Elderly

, 1970
Rachmat Zulkarnain Goesasi, Vina Megitasari, Irma Ruslina Defi   +2 more
openalex   +2 more sources

Hereditary Spastic Paraplegia in Alberta: Lessons from a Well‐Defined Cohort Including the Indigenous Population

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Hereditary spastic paraplegias (HSP) are rare disorders sharing common features of leg spasticity with gait impairment. Simple and complex forms are recognized; over 50% of cases remain unsolved genetically. Little is known about the genetics of HSP among Indigenous Peoples. Objectives To describe clinical, radiological, and genetic
Ekhlas Assaedi, Setareh Ashtiani, Mehrdad A. Estiar, Ziv Gan‐Or, Erica D. McKenzie, Aakash Shetty, Guy Rouleau, Oksana Suchowersky   +7 more
wiley   +1 more source